کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2753066 | 1149610 | 2012 | 10 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Epothilones in Development for Non–Small-Cell Lung Cancer: Novel Anti-Tubulin Agents With the Potential to Overcome Taxane Resistance Epothilones in Development for Non–Small-Cell Lung Cancer: Novel Anti-Tubulin Agents With the Potential to Overcome Taxane Resistance](/preview/png/2753066.png)
Progress in the treatment of non–small-cell lung cancer (NSCLC) will require the introduction of new agents as well as better use of existing therapies. Targeted therapies are likely to have a profound effect on the treatment of NSCLC after identification of patients who are most likely to benefit. The epothilones are novel anti-tubulin agents derived from Sorangium cellulosum. β III tubulin overexpression has been implicated as a mechanism of anti-tubulin resistance that can be overcome by epothilones. Several epothilones have advanced to clinical trials; ixabepilone (BMS247550, aza-epothilone B, Bristol-Myers Squibb, New York, NY), patupilone (EPO906, Novartis, Basel, Switzerland) and sagopilone (ZK-EPO, ZK-219477, Schering AG, Berlin-Wedding, Germany) are currently in active development. Several of the epothilones, most notably ixabepilone, have demonstrated activity in lung cancer in phase I and II trials, including taxane-resistant patients. Although a phase II study failed to show superior outcome in patients with β III tubulin overexpression, other aspects of the epothilones argue for their continued development.
Journal: Clinical Lung Cancer - Volume 13, Issue 3, May 2012, Pages 171–180